Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2

The utility of remdesivir treatment in COVID-19 patients is currently limited by the necessity to administer this antiviral intravenously, which has generally limited its use to hospitalized patients. Here, we tested a novel, subcutaneous formulation of remdesivir in the rhesus macaque model of SARS...

Descripción completa

Detalles Bibliográficos
Autores principales: Williamson, Brandi N., Pérez-Pérez, Lizzette, Schwarz, Benjamin, Feldmann, Friederike, Holbrook, Myndi G., Singh, Manmeet, Lye, Diane S., Babusis, Darius, Subramanian, Raju, Haddock, Elaine, Okumura, Atsushi, Hanley, Patrick W., Lovaglio, Jamie, Bosio, Catharine M., Porter, Danielle P., Cihlar, Tomas, Mackman, Richard L., Saturday, Greg, de Wit, Emmie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755413/
https://www.ncbi.nlm.nih.gov/pubmed/35032523
http://dx.doi.org/10.1016/j.antiviral.2022.105246

Ejemplares similares

Ejemplares similares